Mirtazapine

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• FDA Prescribing Information: Mirtazapine (Remeron) — MDD; NaSSA mechanism; sedation/appetite stimulation; dose paradox; no sexual dysfunction; agranulocytosis risk; Mirataz veterinary transdermal approval for cat weight loss; favorable OD profile (2023) REGULATORY · 2023
• Plumb's Veterinary Drug Handbook: Mirtazapine — canine/feline appetite stimulant; Mirataz transdermal 2mg/g; feline pharmacokinetics; every-48-hour feline dosing; veterinary MAOI interactions; anorexia in CKD and cancer (2023) REFERENCE · 2023
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• EPA CompTox CTX API: predicted properties for DTXSID0023325 (Mirtazapine) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.